FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance. 2000

B McIver, and S K Grebe, and L Wang, and I D Hay, and A Yokomizo, and W Liu, and J R Goellner, and C S Grant, and D I Smith, and N L Eberhardt
Department of Medicine, Mayo Clinic/Foundation, New Zealand.

OBJECTIVE The chromosomal regions containing the two putative tumour suppressors, fragile histidine triad gene (FHIT) and tumour suppressor gene 101 (TSG101), are deleted frequently in thyroid tumours. We therefore analysed FHIT and TSG101 transcripts in a group of advanced thyroid tumours to establish their role in thyroid tumorigenesis. METHODS Retrospective analysis of FHIT and TSG101 mRNA transcripts and genomic DNA from cryo-preserved thyroid tumours. TP53, previously shown at the genomic level not to be mutated in this cohort of tumours, served as a control. METHODS We analysed nine follicular thyroid carcinomas (FTC), six papillary thyroid carcinomas and six follicular adenomas (FA) and histologically normal thyroid tissue from four of the FA patients. METHODS Single stage and nested reverse transcription polymerase chain reaction (RT-PCR) products of FHIT, TSG101, and TP53 were analysed by agarose or polyacrylamide gel electrophoresis and sequenced. Genomic DNA was also analysed by polymerase chain reaction and sequencing (FHIT) or by Southern blotting (TSG101). Clinical data were correlated with the results of the mutation analysis. RESULTS Truncated FHIT transcripts were observed frequently alongside full length transcripts with nested RT-PCR, most often in FTC, while single stage RT-PCR revealed only normal length transcripts in all tumours. Similar results were obtained for TP53, while abnormal TSG101 transcripts were detectable by single stage RT-PCR. Sequence analysis of the truncated FHIT and TSG101 transcripts revealed mainly exon skipping and alternate RNA processing events. Only a single point mutation (of TSG101) was found. Southern blotting for the TSG101 gene, and PCR amplification and sequencing of the FHIT gene showed no evidence of genomic abnormalities in either case, and there was no evidence of splice site mutations in the FHIT gene, suggesting that the truncated transcripts result from altered RNA processing. There was no relationship between tumour stage, grade or survival and the presence of FHIT or TSG101 abnormalities. CONCLUSIONS Truncated FHIT and TSG101 transcripts in thyroid tumours reflect alternate mRNA splicing events, rather than genomic deletions. Such abnormal RNA processing seems to be common and widespread in thyroid neoplasms, as similar results were obtained by analysis of transcripts of TP53, which we had previously shown not to be mutated in these specimens. Although a pathogenetic role for these aberrant transcripts remains possible, no correlation was found with stage, histological grade or outcome in this small group of advanced thyroid malignancies. Relaxation of mRNA splice control appears to be a feature of follicular cell-derived thyroid neoplasms.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D002291 Carcinoma, Papillary A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed) Carcinomas, Papillary,Papillary Carcinoma,Papillary Carcinomas
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D005260 Female Females

Related Publications

B McIver, and S K Grebe, and L Wang, and I D Hay, and A Yokomizo, and W Liu, and J R Goellner, and C S Grant, and D I Smith, and N L Eberhardt
May 1999, International journal of molecular medicine,
B McIver, and S K Grebe, and L Wang, and I D Hay, and A Yokomizo, and W Liu, and J R Goellner, and C S Grant, and D I Smith, and N L Eberhardt
January 2000, International journal of oncology,
B McIver, and S K Grebe, and L Wang, and I D Hay, and A Yokomizo, and W Liu, and J R Goellner, and C S Grant, and D I Smith, and N L Eberhardt
January 1998, Oncology reports,
B McIver, and S K Grebe, and L Wang, and I D Hay, and A Yokomizo, and W Liu, and J R Goellner, and C S Grant, and D I Smith, and N L Eberhardt
February 2000, Leukemia & lymphoma,
B McIver, and S K Grebe, and L Wang, and I D Hay, and A Yokomizo, and W Liu, and J R Goellner, and C S Grant, and D I Smith, and N L Eberhardt
September 2001, Experimental & molecular medicine,
B McIver, and S K Grebe, and L Wang, and I D Hay, and A Yokomizo, and W Liu, and J R Goellner, and C S Grant, and D I Smith, and N L Eberhardt
June 2010, Brain research,
B McIver, and S K Grebe, and L Wang, and I D Hay, and A Yokomizo, and W Liu, and J R Goellner, and C S Grant, and D I Smith, and N L Eberhardt
January 1999, Oncology reports,
B McIver, and S K Grebe, and L Wang, and I D Hay, and A Yokomizo, and W Liu, and J R Goellner, and C S Grant, and D I Smith, and N L Eberhardt
October 1997, Oncogene,
B McIver, and S K Grebe, and L Wang, and I D Hay, and A Yokomizo, and W Liu, and J R Goellner, and C S Grant, and D I Smith, and N L Eberhardt
April 1998, International journal of cancer,
B McIver, and S K Grebe, and L Wang, and I D Hay, and A Yokomizo, and W Liu, and J R Goellner, and C S Grant, and D I Smith, and N L Eberhardt
January 2002, Research communications in molecular pathology and pharmacology,
Copied contents to your clipboard!